Since its inception in 1999, the primary objective of the T32 Urologic Oncology Research Training Program at Memorial Sloan Kettering Cancer Center (MSK) has been to train select urologists for productive careers in translational research in urologic oncology. Dedicated research training in urologic oncology is essential to the mission of the National Cancer Institute (NCI) to reduce morbidity and mortality from genitourinary cancers, which cause about 10% of all cancer-related deaths in the United States and which are expected to rise steadily in incidence as the population ages. For the proposed funding period, we seek to continue our interactive, multidisciplinary research training strategy that integrates the following: (1) a multidisciplinary faculty of basic, clinical, and translational researchers spanning the disciplines of surgery, medicine, cancer biology and therapeutics, molecular pathology and genetics, immunotherapy, molecular radiology, biostatistics and epidemiology, and laboratory medicine, (2) an intensive mentored research practicum tailored to the T32 trainee?s research interests and goals, (3) a core curriculum of required didactic and discussion-based courses to enhance the quality of the hands-on research training, (4) structured career development workshops in grant writing and career development awards, and (5) elective activities that will allow T32 trainees to further immerse themselves in the world of cancer research and to network with peers and established leaders. Each year, 2 highly committed postdoctoral trainees from the Urologic Oncology Fellowship Program at MSK are selected for the T32 Urologic Oncology Research Training Program. They must have an MD, must have completed residency training in urology, and must be board-eligible urologists. These 2 trainees are supported by this T32 training grant during 2 years dedicated to urologic oncology research training, with appointment to the 2nd year contingent on suitable progress. At the completion of their training, graduates of theT32 Urologic Oncology Research Training Program are expected to be attractive candidates for junior faculty appointments at research-focused academic organizations. In the past 10 years, 90% of T32 trainee graduates have matriculated to faculty positions at academic institutions and are engaged in laboratory and/or clinical research aimed at understanding and overcoming genitourinary cancers.
The T32 Urologic Oncology Research Training Program at Memorial Sloan Kettering Cancer Center (MSK) trains qualified urologists for academic careers as clinician-scientists focused on eliminating suffering and death from genitourinary cancers, which comprise 21% of all non-skin cancers and cause 10% of all cancer deaths in the United States.
|Lee, Byron H; Feifer, Andrew; Feuerstein, Michael A et al. (2018) Validation of a Postoperative Nomogram Predicting Recurrence in Patients with Conventional Clear Cell Renal Cell Carcinoma. Eur Urol Focus 4:100-105|
|Mendonca, Shawn J; Sanchez, Alejandro; Blum, Kyle A et al. (2018) The association of renal cell carcinoma with gastrointestinal stromal tumors. J Surg Oncol 117:1716-1720|
|Becerra, Maria F; Reznik, Ed; Redzematovic, Almedina et al. (2018) Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma. Eur Urol Focus 4:986-994|
|Kashan, Mahyar; Ghanaat, Mazyar; Hötker, Andreas M et al. (2018) Cystic Renal Cell Carcinoma: A Report on Outcomes of Surgery and Active Surveillance in Patients Retrospectively Identified on Pretreatment Imaging. J Urol 200:275-282|
|Isharwal, Sumit; Huang, Hongying; Nanjangud, Gouri et al. (2018) Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma. Hum Pathol 77:63-69|
|Casuscelli, Jozefina; Weinhold, Nils; Gundem, Gunes et al. (2017) Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma. JCI Insight 2:|
|Hsieh, James J; Manley, Brandon J; Khan, Nabeela et al. (2017) Overcome tumor heterogeneity-imposed therapeutic barriers through convergent genomic biomarker discovery: A braided cancer river model of kidney cancer. Semin Cell Dev Biol 64:98-106|
|Li, Qiang; Assel, Melissa; Benfante, Nicole et al. (2017) Clinical Outcomes in Patients with Panurothelial Carcinoma Treated with Radical Nephroureterectomy Following Cystectomy for Metachronous Recurrence. J Urol 198:546-551|
|Winer, Andrew G; Vertosick, Emily A; Ghanaat, Mazyar et al. (2017) Prognostic value of lymph node yield during nephroureterectomy for upper tract urothelial carcinoma. Urol Oncol 35:151.e9-151.e15|
|Dong, Yiyu; Manley, Brandon J; Becerra, Maria F et al. (2017) Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples. Eur Urol Focus 3:590-598|
Showing the most recent 10 out of 202 publications